We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Asceneuron Appoints Peter Van Vlasselaer as Chairman PR Newswire LAUSANNE, Switzerland and CAMBRIDGE, Ma., January 17, 2019 LAUSANNE, Switzerland and CAMBRIDGE, Ma., January 17, 2019 /PRNewswire/...
Lilly Completes Acquisition of ARMO BioSciences PR Newswire INDIANAPOLIS, June 22, 2018 INDIANAPOLIS, June 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the...
WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders PR Newswire NEW YORK, May 14, 2018 NEW YORK, May 14, 2018 /PRNewswire/ -- WeissLaw LLP is...
Shares of health-care companies rose as deal activity lured investors back into the biotech sub sector. In the latest sign that Big Pharma is optimistic about the prospects of immunotherapy cancer...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ARMO BioSciences, Inc. PR Newswire NEW YORK, May 10, 2018 NEW YORK, May 10, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating...
By Austen Hufford Eli Lilly and Co. is buying ARMO BioSciences Inc. for $1.6 billion, the latest investment in the hot area of immunotherapy cancer treatments. Immunotherapy, or immune-cell...
ARMO BioSciences Alert: Johnson Fistel Investigates Proposed Sale of ARMO BioSciences, Inc.; Is $50 a Fair Price? PR Newswire SAN DIEGO, May 10, 2018 SAN DIEGO, May 10, 2018 /PRNewswire/...
Lilly Announces Agreement To Acquire ARMO BioSciences $1.6 billion transaction will bolster Lilly's clinical portfolio with ARMO's lead immuno-oncology asset, pegilodecakin, which is being...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions